These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 17631051)
1. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides. Sakakura K; Chikamatsu K; Furuya N; Appella E; Whiteside TL; Deleo AB Clin Immunol; 2007 Oct; 125(1):43-51. PubMed ID: 17631051 [TBL] [Abstract][Full Text] [Related]
2. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999 [TBL] [Abstract][Full Text] [Related]
3. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. Hoffmann TK; Nakano K; Elder EM; Dworacki G; Finkelstein SD; Appella E; Whiteside TL; DeLeo AB J Immunol; 2000 Nov; 165(10):5938-44. PubMed ID: 11067956 [TBL] [Abstract][Full Text] [Related]
4. CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer. Chikamatsu K; Sakakura K; Takahashi G; Okamoto A; Furuya N; Whiteside TL; DeLeo AB; Masuyama K Cancer Immunol Immunother; 2009 Sep; 58(9):1441-8. PubMed ID: 19184003 [TBL] [Abstract][Full Text] [Related]
5. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma. Cicinnati VR; Zhang X; Yu Z; Ferencik S; Schmitz KJ; Dworacki G; Kaczmarek E; Oldhafer K; Frilling A; Baba HA; Schmid KW; Grosse-Wilde H; Broelsch CE; DeLeo AB; Gerken G; Beckebaum S Int J Cancer; 2006 Dec; 119(12):2851-60. PubMed ID: 16998881 [TBL] [Abstract][Full Text] [Related]
6. p53 as an immunotherapeutic target in head and neck cancer. Hoffmann TK; Bier H; Donnenberg AD; Whiteside TL; De Leo AB Adv Otorhinolaryngol; 2005; 62():151-60. PubMed ID: 15608425 [TBL] [Abstract][Full Text] [Related]
7. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724 [TBL] [Abstract][Full Text] [Related]
8. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck. Ito D; Visus C; Hoffmann TK; Balz V; Bier H; Appella E; Whiteside TL; Ferris RL; DeLeo AB Int J Cancer; 2007 Jun; 120(12):2618-24. PubMed ID: 17294448 [TBL] [Abstract][Full Text] [Related]
9. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins. Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748 [TBL] [Abstract][Full Text] [Related]
10. Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck. Sirianni N; Ha PK; Oelke M; Califano J; Gooding W; Westra W; Whiteside TL; Koch WM; Schneck JP; DeLeo A; Ferris RL Clin Cancer Res; 2004 Oct; 10(20):6929-37. PubMed ID: 15501971 [TBL] [Abstract][Full Text] [Related]
11. CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck. Andrade Filho PA; Ito D; Deleo AB; Ferris RL Cancer Immunol Immunother; 2010 Oct; 59(10):1561-8. PubMed ID: 20577877 [TBL] [Abstract][Full Text] [Related]
12. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope. Hoffmann TK; Loftus DJ; Nakano K; Maeurer MJ; Chikamatsu K; Appella E; Whiteside TL; DeLeo AB J Immunol; 2002 Feb; 168(3):1338-47. PubMed ID: 11801674 [TBL] [Abstract][Full Text] [Related]
13. The wild-type sequence (wt) p53(25-35) peptide induces HLA-DR7 and HLA-DR11-restricted CD4+ Th cells capable of enhancing the ex vivo expansion and function of anti-wt p53(264-272) peptide CD8+ T cells. Ito D; Albers A; Zhao YX; Visus C; Appella E; Whiteside TL; DeLeo AB J Immunol; 2006 Nov; 177(10):6795-803. PubMed ID: 17082593 [TBL] [Abstract][Full Text] [Related]
14. Wildtype p53-specific antibody and T-cell responses in cancer patients. Pedersen AE; Stryhn A; Justesen S; Harndahl M; Rasmussen S; Donskov F; Claesson MH; Pedersen JW; Wandall HH; Svane IM; Buus S J Immunother; 2011; 34(9):629-40. PubMed ID: 21989411 [TBL] [Abstract][Full Text] [Related]
15. Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer. Albers AE; Qian X; Kaufmann AM; Mytilineos D; Ferris RL; Hoffmann TK; DeLeo AB Sci Rep; 2018 Jul; 8(1):10716. PubMed ID: 30013227 [TBL] [Abstract][Full Text] [Related]
16. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Albers AE; Ferris RL; Kim GG; Chikamatsu K; DeLeo AB; Whiteside TL Cancer Immunol Immunother; 2005 Nov; 54(11):1072-81. PubMed ID: 15959774 [TBL] [Abstract][Full Text] [Related]
17. Identification of p53 peptides recognized by CD8(+) T lymphocytes from patients with bladder cancer. Ferriès E; Connan F; Pagès F; Gaston J; Hagnéré AM; Vieillefond A; Thiounn N; Guillet J; Choppin J Hum Immunol; 2001 Aug; 62(8):791-8. PubMed ID: 11476902 [TBL] [Abstract][Full Text] [Related]
18. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Visus C; Ito D; Amoscato A; Maciejewska-Franczak M; Abdelsalem A; Dhir R; Shin DM; Donnenberg VS; Whiteside TL; DeLeo AB Cancer Res; 2007 Nov; 67(21):10538-45. PubMed ID: 17974998 [TBL] [Abstract][Full Text] [Related]
19. Two novel squamous cell carcinoma antigen-derived HLA-A*0201-binding peptides induce in vitro and in vivo CD8+ cytotoxic T lymphocyte responses. Duan ZL; Wang ZB; Guo JL; Liu WQ; Hu J; Li J; Wang SN; Li Q; Wen JS Int J Oncol; 2013 Apr; 42(4):1482-92. PubMed ID: 23426430 [TBL] [Abstract][Full Text] [Related]
20. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Scheibenbogen C; Lee KH; Mayer S; Stevanovic S; Moebius U; Herr W; Rammensee HG; Keilholz U Clin Cancer Res; 1997 Feb; 3(2):221-6. PubMed ID: 9815676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]